Diabetes

Explore the complexities of Diabetes research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against Diabetes with flcube.com.

Five Innovative Therapies Enter the Rare Disease R&D Pilot Initiative – Spanning Blau Syndrome, Angelman Syndrome, ALS and Charcot‑Marie‑Tooth Disease
Policy / Regulatory

Five Innovative Therapies Enter the Rare Disease R&D Pilot Initiative – Spanning Blau Syndrome, Angelman Syndrome, ALS and Charcot‑Marie‑Tooth Disease

Accropeutics, Anyea, Myrobalan Therapeutics and ReviR Therapeutics announced that AC‑101, ANY‑108, ANY‑112, MRO‑001HS and RTX‑117 have been admitted into the pilot initiative encouraging the research and development of innovative therapies…

Suzhou Rigerna Therapeutics' RG002C0106 Injection Supplemental Application Accepted by China's CDE – Class 1 Chemical Drug Enters Regulatory Review

Suzhou Rigerna Therapeutics’ RG002C0106 Injection Supplemental Application Accepted by China’s CDE – Class 1 Chemical Drug Enters Regulatory Review

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech's CNS and Brain‑Penetrant Drug Pipeline

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech’s CNS and Brain‑Penetrant Drug Pipeline

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Novo Nordisk to Withdraw All Forms of Levemir in the UK by End‑2026 – DHSC Issues National Patient Safety Alert Mandating Insulin Switches
CompanyDrug

Novo Nordisk to Withdraw All Forms of Levemir in the UK by End‑2026 – DHSC Issues National Patient Safety Alert Mandating Insulin Switches

Sunshine Lake Pharma Wins NMPA Approval for Dual Insulin Analogue Injection – Fixed‑Ratio Degludec/Aspart Targets Fasting and Postprandial Glucose in One Formulation
CompanyDrug

Sunshine Lake Pharma Wins NMPA Approval for Dual Insulin Analogue Injection – Fixed‑Ratio Degludec/Aspart Targets Fasting and Postprandial Glucose in One Formulation

FDA Approves Eli Lilly's Onswik – Once‑Weekly Basal Insulin for Adults With Type 2 Diabetes
CompanyDrug

FDA Approves Eli Lilly’s Onswik – Once‑Weekly Basal Insulin for Adults With Type 2 Diabetes

Novo Nordisk Licenses Hengrui's HRS‑1596 in Up to USD 2.6 Billion Global Deal – Once‑Weekly Oral Candidate for Obesity and Type 2 Diabetes
CompanyDeals

Novo Nordisk Licenses Hengrui’s HRS‑1596 in Up to USD 2.6 Billion Global Deal – Once‑Weekly Oral Candidate for Obesity and Type 2 Diabetes

Novo Nordisk's Once‑Weekly CagriSema Proves Superior to Tirzepatide in Head‑to‑Head Weight Loss Trial – REDEFINE 9 Delivers 21.0% Reduction vs Placebo
CompanyDrug

Novo Nordisk’s Once‑Weekly CagriSema Proves Superior to Tirzepatide in Head‑to‑Head Weight Loss Trial – REDEFINE 9 Delivers 21.0% Reduction vs Placebo

CSPC Pharmaceutical Initiates Phase II Trial of SYH2069 – Novel Long‑Acting GLP‑1R/GIPR Dual Agonist with Dual‑Biased Activity for Adult Type 2 Diabetes
CompanyDrug

CSPC Pharmaceutical Initiates Phase II Trial of SYH2069 – Novel Long‑Acting GLP‑1R/GIPR Dual Agonist with Dual‑Biased Activity for Adult Type 2 Diabetes

CompanyDrug

NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China

CompanyDrug

GanLee’s GZC8072 Wins NMPA IND Approval for Once‑Weekly Oral Type 2 Diabetes Candidate

Show More